Gilead’s hopes for an approval in hepatitis delta virus (HDV) infection and compensated liver disease will have to wait following an FDA rejection.

BioMarin

During its third-quarter earnings report, BioMarin Pharmaceutical noted that the FDA plans to hold an advisory committee meeting to discuss the company’s gene therapy for hemophilia A. 

PTC Therapeutics

PTC Therapeutics forged a financing deal valued at up to $1 billion with Blackstone that will allow it to deliver one new therapy every two or three years, the New Jersey-based biotech reported.

Sanofi

French drugmaker Sanofi on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines, spurring a rise in its battered share price.

Gilead Sciences Inc. on Thursday posted a higher-than-expected third-quarter profit on the back of strong demand for its HIV and cancer drugs, which helped offset lower sales of its COVID-19 antiviral drug and acquisition expenses.

Leading consulting firm McKinsey & Co. has agreed to settle claims by hundreds of U.S. local governments and school districts around the country that it fueled an epidemic of opioid addiction through its work for bankrupt OxyContin maker Purdue Pharma LP and other drug companies.

Merck & Co. on Thursday reported better-than-expected third-quarter sales and profit on a jump in demand for blockbuster cancer immunotherapy Keytruda and human papillomavirus vaccine Gardasil.

Italy’s tax authorities are investigating profits reported by Pfizer Inc.’s local unit Pfizer Italia srl, two sources with knowledge of the matter told Reuters on Thursday.

GSK logo

British drugmaker GSK said on Thursday it would not be proceeding with regulatory submissions of its experimental treatment for moderate-to-severe rheumatoid arthritis (RA) after the drug failed to meet a key goal in a study.

Merck

The company stated that Chief Executive Officer Rob Davis would succeed Chairman Ken Frazier, taking on the additional role effective Dec. 1.